Oxford Biomedica signs licence, supply deal with Cabaletta Bio

5th Jan 2022 07:29

(Sharecast News) - Gene and cell therapy group Oxford Biomedica on Wednesday said it had signed a new license and supply agreement on its LentiVector platform with US-based Cabaletta Bio.
The deal gives Cabaletta a non-exclusive licence for LentiVector to be used on Chimeric autoantibody receptor T programme, DSG3-CAART, for autoimmune disease.

No financial details were revealed, but Oxford Biomendica said the arrangements of the LSA were "in line with comparable deals the group has previously secured".

Top Risers

Share	Price	Change
Helix Exploration (HEX)	20.80	0%
Totally (TLY)	6.60	0%
Angle (AGL)	21.25	0%
Asiamet Res (ARS)	1.30	0%
PipeHawk (PIP)	7.50	0%

Top Fallers

Share	Price	Change
Scirocco Energy (SCIR)	0.24	0%
Regtech Open (RTOP)	2.29	0%
Ceps (CEPS)	18.00	0%
Deltic Energy (DELT)	17.00	0%
Cloudified Holdings Limited (CHL)	6.00	0%

Top By Volume

Share	Price	Volume
Beacon Energy. (BCE)	0.065	0
Cap-xx (CPX)	0.0825	0
Lloyds (LLOY)	53.72	0
Mosman Oil Gas (MSMN)	0.02	0
Supply@me Cap (SYME)	0.024	0

All prices are delayed by at least 15 minutes. Share Compare cannot be held responsible for the accuracy of share prices shown on this website, and investors should be aware that share prices can go down as well as up. Share Compare does not offer advice, and is not regulated by the Financial Conduct Authority.